CHAMPIONS ONCOLOGY, INC.: financing cash flow
Financing cash flow for CHAMPIONS ONCOLOGY, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All CHAMPIONS ONCOLOGY, INC. financial histories
What this measure means
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-05-01 to 2026-04-30. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-05-01 | 2026-04-30 | 99,000 | USD | 2026-07-27 | 10-K · 0001628280-26-049834 |
| 2024-05-01 | 2025-04-30 | 170,000 | USD | 2026-07-27 | 10-K · 0001628280-26-049834 |
| 2023-05-01 | 2024-04-30 | -527,000 | USD | 2025-07-23 | 10-K · 0001628280-25-035765 |
| 2022-05-01 | 2023-04-30 | 11,000 | USD | 2024-07-19 | 10-K · 0001628280-24-032321 |
| 2021-05-01 | 2022-04-30 | 207,000 | USD | 2023-07-24 | 10-K · 0001628280-23-025464 |
| 2020-05-01 | 2021-04-30 | 1,195,000 | USD | 2022-07-22 | 10-K · 0001628280-22-019309 |
| 2019-05-01 | 2020-04-30 | 4,420,000 | USD | 2021-07-26 | 10-K · 0001628280-21-014464 |
| 2018-05-01 | 2019-04-30 | 1,203,000 | USD | 2020-07-28 | 10-K · 0001628280-20-010734 |
| 2017-05-01 | 2018-04-30 | 13,000 | USD | 2019-07-29 | 10-K · 0001628280-19-009139 |
| 2016-05-01 | 2017-04-30 | 4,316,000 | USD | 2018-07-30 | 10-K · 0001628280-18-009773 |
| 2015-05-01 | 2016-04-30 | -42,000 | USD | 2017-07-28 | 10-K · 0001628280-17-007429 |
| 2014-05-01 | 2015-04-30 | 13,210,000 | USD | 2016-07-29 | 10-K · 0001628280-16-017936 |
| 2012-05-01 | 2013-04-30 | 9,141,000 | USD | 2013-07-26 | 10-K · 0001144204-13-041406 |
| 2011-05-01 | 2012-04-30 | 97,000 | USD | 2013-07-26 | 10-K · 0001144204-13-041406 |
| 2010-05-01 | 2011-04-30 | 8,083,000 | USD | 2012-07-18 | 10-K · 0001144204-12-040031 |
Related financial histories
- CHAMPIONS ONCOLOGY, INC.: total assets
- CHAMPIONS ONCOLOGY, INC.: total liabilities
- CHAMPIONS ONCOLOGY, INC.: stockholders equity
- CHAMPIONS ONCOLOGY, INC.: cash and cash equivalents
- CHAMPIONS ONCOLOGY, INC.: net income or loss
- CHAMPIONS ONCOLOGY, INC.: operating cash flow
- CHAMPIONS ONCOLOGY, INC.: capital expenditure payments
- CHAMPIONS ONCOLOGY, INC.: contract revenue excluding tax
- CHAMPIONS ONCOLOGY, INC.: investing cash flow
- CHAMPIONS ONCOLOGY, INC.: retained earnings or deficit
- CHAMPIONS ONCOLOGY, INC.: basic weighted-average shares
- CHAMPIONS ONCOLOGY, INC.: diluted weighted-average shares
- CHAMPIONS ONCOLOGY, INC.: basic earnings per share
- CHAMPIONS ONCOLOGY, INC.: diluted earnings per share
- CHAMPIONS ONCOLOGY, INC.: income tax expense or benefit
- CHAMPIONS ONCOLOGY, INC.: net property, plant and equipment
- CHAMPIONS ONCOLOGY, INC.: share-based compensation expense
- CHAMPIONS ONCOLOGY, INC.: operating income or loss
- CHAMPIONS ONCOLOGY, INC.: current assets
- CHAMPIONS ONCOLOGY, INC.: current liabilities
- CHAMPIONS ONCOLOGY, INC.: current accounts payable
- CHAMPIONS ONCOLOGY, INC.: goodwill carrying amount
- CHAMPIONS ONCOLOGY, INC.: net current accounts receivable
- CHAMPIONS ONCOLOGY, INC.: common-stock repurchase payments
- CHAMPIONS ONCOLOGY, INC.: operating expenses
- CHAMPIONS ONCOLOGY, INC.: research and development expense
Inspect the source
- Entity
- CHAMPIONS ONCOLOGY, INC. / CIK 0000771856
- Captured
- 2026-09-19T15:03:10.942Z
- SEC response SHA-256
5e12cce913e8fa6eeaa622fe38f19d410a1285352d1d5bd54527ac657d9a988a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000771856.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))